<DOC>
	<DOCNO>NCT00050154</DOCNO>
	<brief_summary>The purpose study characterize hematological response rate , well parameter efficacy safety induce tipifarnib patient high-risk myelodysplastic syndrome ( MDS ) . Tipifarnib belong class drug call Farnesyl Transferase Inhibitors ( FTI ) . It block protein make cancer cell grow .</brief_summary>
	<brief_title>Study Tipifarnib Patients With High-Risk Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>Treatment tipifarnib give one period time call cycle ( ) . Each cycle 28 day long patient take tipifarnib first 21 day cycle . No medication take last 7 day cycle . On day 1 15 cycle , patient ask side effect occur since last visit . Blood drawn routine test evaluate possible effect tipifarnib white blood cell specific element , measure blood . The study doctor decide bone marrow aspirate biopsy take . Tipifarnib give patient 's disease worsen develop unacceptable side effect withdraw consent receive tipifarnib . When tipifarnib treatment end patient leaf study early , ask come final visit . The study doctor decide blood draw , bone marrow aspirate biopsy need take . Tipifarnib 300 mg administer orally three 100 mg tablet twice daily first 21 day 28-day cycle . Tipifarnib administer patient discontinues treatment due disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<criteria>Pathological evidence MDS Not 1 prior cytotoxic treatment MDS Able take oral study drug Able understand provide sign informed consent Refractory anemia ( RA ) RA excess blast ( RAEB ) patient RAEB &lt; = 10 % marrow blast Treatmentrelated MDS , treat chemotherapy le 3 year ago Not adequately recover treatmentrelated nonhematological toxicity Refractory platelet transfusion Candidates hematopoietic stem cell transplantation Previous therapy farnesyl transferase inhibitor Prior extensive radiation therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>R115777</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>Tipifarnib</keyword>
	<keyword>Zarnestra</keyword>
</DOC>